Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Nonpsychoactive, neuroprotective cannabinoids available for licensing from NIH

Jan. 7, 1999

Mayo Clinic closes in on gene causing PD and essential tremor

Jan. 5, 1999

Second phase II trial commences for SIB-1508Y

Jan. 5, 1999

CytoTherapeutics granted U.S. patent covering human neural stem cells

Jan. 5, 1999

Warner-Lambert claims new kappa-opioid agonists and their use

Jan. 4, 1999

Novel compounds synthesized at SmithKline Beecham act at several 5-HT receptor subtypes

Jan. 4, 1999

New treatment for AIDS-related pain progresses to clinical testing

Jan. 4, 1999

Novo Nordisk describes novel muscarinic cholinergic receptor modulators

Dec. 30, 1998

First U.S. marketing approval for Cephalon: Provigil cleared for narcolepsy-associated EDS

Dec. 29, 1998

YM-872: neuroprotective effects in animal model indicate potential in acute ischemic stroke

Dec. 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...